Latest News and Insights Articles & Interviews Press Releases 2026 Psilera Closes Oversubscribed $8.8M Seed Funding Round to Accelerate Neuroplastogen PSIL-006 Into the Clinic (5/28/26) Psilera Commends Landmark Executive Order Prioritizing Psychedelic Therapies (4/20/26) Distinguished Neuroscience Expert Magali Haas, MD/PhD, Joins Psilera as Chief Medical Officer (1/8/26) 2025 Psilera Inc. Secures National Institutes of Health Grant for AUD Research (10/2/25) Healthcare Industry Veteran Scott Rairigh Joins Psilera to Lead Corporate Development (9/4/25) Psilera Inc. & atai Life Sciences Announce Licensing Agreement for DMT Patent Portfolio (2/20/25) Biotechnology Company Psilera Convenes Prominent Industry Leaders & Patient Advocates for First FTD Research Summit (1/15/25) Psilera Collaborates with Drug Development Leader Hesperos to Advance Preclinical Modeling of PSIL-006 for Frontotemporal Dementia (1/9/25) 2024 USF Research Foundation Proudly Endorses and Invests In Psilera's FTD Research (9/5/24) Psilera Receives Positive Preclinical In Vivo Data for FTD Candidate PSIL-006 (8/27/24) Dr. Magali Haas, MD-PhD Joins Psilera as an Independent Board Member (3/26/24) Psilera Announces Lead Indication for PSIL-006: Behavioral Variant Frontotemporal Dementia (bvFTD) (1/23/24) 2023 Psilera: Tampa Bay HealthTech Company of the Year and a Finalists for Company to Watch by GrowFL (8/23/23) Psilera Receives Allowance on Flagship Patent Securing Novel Compound Library (8/15/23) Psilera Unveils Psilocybin Derivative PSIL-006 As Lead Clinical Candidate (5/25/23) Non-Hallucinogenic Drug Candidates for First-in-Human Studies (3/30/23) 2022 Psilera Presenting on International Stage at Biotech Showcase (12/8/22) Psilera Co-Founders' Summer Conference Announcement (10/20/22) First Patent Allowance for Transdermal Patch Formulations (9/4/22) 2022 Wall Street Journal Health Forum and American Chemical Society Meeting (3/17/22) USF and Morsani College of Medicine Funding Match for NCE's (3/8/22) Press Kit
